|
|
|
European Pharmaceutical Contractor
|
EPC has a new owner and this is the first edition of any of our three magazines - EPC, EBR and PMPS - that has been produced entirely under the new management of Samedan Ltd. As we go forward into 2002 we confidently believe that all three magazines will go from strength to strength and build on the quality that our readers have come to expect. It is also EPC's fifth anniversary and our 21st issue, with over 400 editorial articles behind us covering an extraordinary range of topics. It is not surprising then that we return to themes that may be familiar to some of our regular readers. But this only emphasises their importance and general interest.
One of these important themes is that of the role of 'electronics' in clinical development. In this issue we have six articles that address this theme. Over the years we have seen a number of articles that have emphasised the promise of electronics in making a major contribution to the speeding up of clinical trials. These articles reinforce the promise, but a promise it remains, and it will be, in my opinion, several years before electronic trials replace the more traditional, albeit slower, methodology. In a related article, Clarke Graham's article on brand protection discusses how the Internet can be both a benefit and a threat by providing global branding reach.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
